Postoperative pain in burned patients with a burn excision area between 2 and 12 % of total body surface area.
Conditions
Interventions
Trade Name: Neurontín
Pharmaceutical Form: Capsule*
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Enteral use (Noncurrent)
Trade Name: Lyrica
Pharmaceutical For
Sponsors
Anaesthesiology Department. Universitary Hospital Vall d'Hebron, Barcelona.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Both sexes Age between 18 and 70 years old Admision to the Burn Unit of Hospital Universitari Vall d'Hebron, Barcelona, for surgical treatment Burn excision between 2 and 12 % of body surfece area under general anaesthesia Estimated length of stay longer than three days Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Inability to operate a PCA device Neurological deficits Psychiatric disorders Opioid abuse Pregnancy Use of local anaesthetics Daily NSAID intake Renal failure Allegy to the study medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Efficacy of gabapentin and pregabalin on opioid consumption during the 24 h after surgery in burned patients with a burn excision area between 2 and 12 % of total body surface area.;Secondary Objective: VAS pain evaluation in the immediate postoperative period (24 hours) Comparison of gabapentinoids effect to dexketoprofen effect on postoperative analgesia in burned patients Side effects evaluation ;Primary end point(s): Opioid consumption during the first 24 hours following surgery | — |
Countries
Spain
Outcome results
None listed